We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma

This study has been terminated.
(Low recruitment due to change in standard of care)
Sponsor:
ClinicalTrials.gov Identifier:
NCT01810016
First Posted: March 13, 2013
Last Update Posted: June 17, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Institute of Cancer Research, United Kingdom
Information provided by (Responsible Party):
Ludwig Institute for Cancer Research
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: December 2016
  Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)